BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Isakov V. Metabolic dysfunction-associated steatotic liver disease: A story of muscle and mass. World J Gastroenterol 2025; 31(20): 105346 [PMID: 40495947 DOI: 10.3748/wjg.v31.i20.105346]
URL: https://www.wjgnet.com/1007-9327/full/v31/i20/105346.htm
Number Citing Articles
1
Stavros P. Papadakos, Chara Georgiadou, Eva Kassi, Rallia-Iliana Velliou, Antonios Chatzigeorgiou. Animal models of lean metabolic dysfunction-associated steatotic liver disease (MASLD): bridging pathogenesis and novel drug discoveryExpert Opinion on Drug Discovery 2025; 20(12): 1683 doi: 10.1080/17460441.2025.2579124
2
Maria-Zinaida Dobre, Bogdana Virgolici, Daciana Costina Andrada Dunca-Stefan, Ioana-Cristina Doicin, Iulia-Ioana Stanescu-Spinu. Inflammation—Insulin Resistance Crosstalk and the Central Role of MyokinesInternational Journal of Molecular Sciences 2025; 27(1): 60 doi: 10.3390/ijms27010060
3
Mengyan Zhao, Tao Guo, Chaoyang Liu. Exploring the impact of childhood obesity on sarcopenia-related traits: A 2-way Mendelian randomization analysisMedicine 2026; 105(8): e44812 doi: 10.1097/MD.0000000000044812
4
Vaynika Gupta, Ashwin Krishnamoorthy. Skeletal muscle alterations in metabolic dysfunction-associated steatotic liver disease: A critical review of diagnostic, mechanistic, and therapeutic intersectionsWorld Journal of Gastroenterology 2025; 31(31): 110481 doi: 10.3748/wjg.v31.i31.110481
5
Shinya Sato, Hiroaki Takaya, Tadashi Namisaki, Tatsuya Nakatani, Jun-ichi Hanatani, Yuki Tsuji, Koh Kitagawa, Norihisa Nishimura, Kosuke Kaji, Hitoshi Yoshiji. Diabetes as a Risk Factor for Sarcopenia in Patients with MASH-Related CirrhosisJournal of Clinical Medicine 2025; 14(24): 8691 doi: 10.3390/jcm14248691
6
Almir Fajkić, Yun Wah Lam, Rijad Jahić, Ivan Ćavar, Antonio Markotić, Andrej Belančić. From Adipose Dysfunction to Multi-Organ Steatosis: Defining the Metabolic Steatotic AxisCurrent Issues in Molecular Biology 2026; 48(2): 178 doi: 10.3390/cimb48020178
7
Masafumi Oyama, Tadashi Namisaki, Akihiko Shibamoto, Satoshi Iwai, Masayoshi Takami, Yuki Tsuji, Yukihisa Fujinaga, Hiroaki Takaya, Takashi Inoue, Norihisa Nishimura, Shinya Sato, Koh Kitagawa, Kosuke Kaji, Akira Mitoro, Kiyoshi Asada, Hiroyuki Masuda, Junichi Hanatani, Hitoshi Yoshiji. Creatinine-to-Cystatin C Ratio Combined with FIB-4 and ELF for Noninvasive Fibrosis Assessment in MASLDInternational Journal of Molecular Sciences 2025; 26(19): 9560 doi: 10.3390/ijms26199560
8
André J. Scheen. GLP-1-derived therapies and sarcopenia: plea for a specific focus on at risk special populationsDiabetes & Metabolism 2026; 52(1): 101708 doi: 10.1016/j.diabet.2025.101708
9
Carlo Acierno, Fannia Barletta, Alfredo Caturano, Riccardo Nevola, Ferdinando Carlo Sasso, Luigi Elio Adinolfi, Luca Rinaldi. Alcohol Consumption and Liver Metabolism in the Era of MASLD: Integrating Nutritional and Pathophysiological InsightsNutrients 2025; 17(13): 2229 doi: 10.3390/nu17132229